Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Die Partnerschaft mit Altem ist m.E. nicht neu, aber der Artikel liest sich trotzdem ganz nett in Bezug auf Indien: Cellink Expands its Bioconvergence Footprint in India https://3dprint.com/283247/cellink-expands-its-bioconvergence-footprint-in-india/

Masmo, dein Gebet wurde erhört.

Wäre schön, wenn wir die Seitwärtsphase jetzt mal nach oben brechen und wieder höhere Kurse anstreben.

Hab mich gewundert daß da auf einmal Bico in meinem Depot steht, Danke für die Infos hier...👍👍

Cellink ist ja quasi nur ein Produkt von in Zukunft vielen. 👍

Ich kann die Begründung aber auch verstehen. Der Begriff Cellink umfasst ja erstmal nur das Kerngeschäft. Wenn man, zusammen mit den übernommenen Unternehmen, ein breit aufgestelltes Biotechnologie-Unternehmen aufstellen will, passt das mit dem neuen Namen schon..

Mir auch. Cellink wird auch weiterhin Bestandteil von BICO sein.

Cellink hat mir eigentlich gut gefallen

CELLINK has initiated the process of changing name to BICO Today, the plans for the name change from CELLINK to BICO have been announced in conjunction with the publication of the notice to the extraordinary general meeting. The new name reflects the Group's strategic bio convergence agenda and emphasizes that the company now comprises a Group consisting of several subsidiaries divided into three business areas. In addition, the journey begins to, over time, build a world-famous company by unleashing the power and future potential of a new brand. The first step in the process for changing name will be through the resolution at the Extraordinary General Meeting on August 6, 2021, and by amending the Articles of Association and thereafter register with the Swedish Companies Registration Office.

Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services https://news.cision.com/cellink-ab/r/visikol-partners-with-mattek-to-leverage-their-advanced-cell-culture-models-in-its-suite-of-drug-dis,c3380730 Over the last two months, both MatTek and Visikol have been acquired by CELLINK, the world’s leading bioconvergence company. CELLINK is focused on bringing together, the technologies, products, services, and people required to create the future of medicine. Together, MatTek and Visikol bring significant experience with providing researchers best-in-class in vitro models and services for evaluating the safety, efficacy and pharmacokinetics of therapeutics and personal care products. Today, the two companies are announcing that Visikol will now be leveraging the MatTek portfolio of advanced cell culture models within its drug discovery services.   ...

Stimmt

Schon wieder KE? Keine Ahnung ist eh ein Spekulatives hier. Aber passt eh dann hoffentlich bald wieder zum Nachkauf

Wieso dieser Absturz?

https://mb.cision.com/Main/14960/3375845/1437862.pdf

CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office

CELLINK has entered into an agreement to acquire Discover Echo Inc., an innovative and revolutionary microscopy company https://www.cellink.com/investors/press-release/?r=C224B822E878235E ... Discover Echo is an innovative and revolutionary American company focusing on development, manufacturing, and sales of patented and unique hybrid microscopes that easily transform between Upright and Inverted configurations, merging the capabilities of multiple instruments into one. Discover Echo is expected to grow 65% in 2021 and generate approximately USD 20 million of revenue with a double-digit EBITDA margin....